ACG Clinical Guideline: Management of Crohn’s Disease in Adults

  title={ACG Clinical Guideline: Management of Crohn’s Disease in Adults},
  author={Gary R. Lichtenstein and Edward V. Loftus and Kim L. Isaacs and Miguel Regueiro and Lauren B. Gerson and Bruce E. Sands},
  journal={The American Journal of Gastroenterology},
Crohn’s disease is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influences. The incidence of Crohn’s disease has steadily increased over the past several decades. The diagnosis and treatment of patients with Crohn’s disease has evolved since the last practice guideline was published. These guidelines represent the official practice recommendations of the American College of Gastroenterology and were developed under the auspices of the… 
Is there a standardized practice for the development of international ulcerative colitis and Crohn’s disease treatment guidelines?
The majority of UC and CD guidelines are based on a low/very low quality of evidence and are further weakened due to the lack of homogeneity in specific aspects of management recommendations as well as conflicts of interest.
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
This English version was produced and modified based on the existing updated guidelines in Japanese regarding indications for proceeding with the diagnosis and treatment of inflammatory bowel disease.
Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists.
IBD therapy extends far beyond medications, and other aspects of the overall health and well-being of the patient are critical, including preventive health, nutrition, psycho-behavioral support, addressing patients' concerns around complementary therapy and medication adherence, prevention of disability, and ensuring open communication.
Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications.
  • C. Siegel, C. Bernstein
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2019
Crohn's Disease: Diagnosis and Management.
Patients with Crohn's disease are at increased risk of cancer, osteoporosis, anemia, nutritional deficiencies, depression, infection, and thrombotic events, so maximizing prevention measures is essential in caring for these patients.
First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus
This guideline was stimulated and supported by the Emirates Gastroenterology and Hepatology Society following a systematic review and a Delphi consensus process that provided evidence- and expert opinion-based recommendations about diagnosis, treatment, and management of main complications of ulcerative colitis and Crohn’s disease.
Treatment Algorithms for Crohn’s Disease
Therapy algorithms are given as a guide through different CD scenarios to support the physician’s decision making and with the advantage of good safety profiles over TNF-inhibitors, these drugs will be more frequently used in the near future, also as first-line biologicals, compared to TNFs.
A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn’s Disease in the Elderly Population
Differences exist between adult- and older-onset disease, yet many guidelines do not specifically distinguish the management of these two distinct populations, and balancing symptom management with risks of medical and surgical therapy is an ongoing challenge.
Anti-TNF Therapy in Crohn’s Disease
Anti-TNF (tumour necrosis factor) therapy was approved for use in Crohn’s disease in 1998, and has changed the paradigm of treatment, leading to improved rates of response and remission in patients.
Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice.
  • G. Bonnaud, Y. Bouhnik, L. Peyrin-Biroulet
  • Medicine
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2020


Management of Crohn's disease in adults
These guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and may be updated with pertinent scientific developments at a later time.
Corticosteroids in Crohn’s disease
Alternative classes of medical therapy for Crohn's disease, including modified corticosteroids and a group of new biological therapies, have proven to be efficacious in the management of active and/or quiescent Crohn't disease.
European evidence based consensus on the diagnosis and management of Crohn’s disease: current management
This second section of the European Crohn’s and Colitis Organisation (ECCO) Consensus on the management of Crohn’s disease concerns treatment of active disease, maintenance of medically induced
From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation.
This article reviews the findings that are most helpful in distinguishing various forms of intestinal inflammation and presents a summary of the features that help to differentiate among inflammatory conditions of the bowel, organized by clinical syndrome as presentations of ileitis, proctitis, colitis, and the difficult pouch.
ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease
Health maintenance issues addressed in this guideline include identification, safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, melanoma and non-melanoma skin cancer as well as identification of depression and anxiety and smoking cessation.
The Natural History of Adult Crohn's Disease in Population-Based Cohorts
This comprehensive review summarizes the current knowledge of the natural history of Crohn's disease in adults as reported in population-based studies that include long-term follow-up results.
Corticosteroids for maintenance of remission in Crohn's disease.
The use of conventional systemic corticosteroids in patients with clinically quiescent Crohn's disease does not appear to reduce the risk of relapse over a 24 month period of follow-up.
Adalimumab for the treatment of Crohn’s disease
ADA appears to be effective in inducing and maintain clinical remission in CD, including patients not manageable with IFX, and further on going trials will confirm a positive role for ADA as a new anti-TNF treatment in CD.
The natural history of Crohn’s disease in children: a review of population-based studies
Childhood-onset CD seems to be an aggressive phenotype of the disease, and a trend towards decreasing surgical rate can be observed in newer cohorts paralleled by an increase in immunomodulator use and biologicals.
Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases
Simple demographic and clinical features can guide the clinician in identifying patients at higher risk for disease complications at diagnosis and throughout disease course, however, many of these risk factors have been identified retrospectively and lack validation.